GALXC

Welcome to the Brand page for “GALXC”, which is offered here for Custom manufacture of oligonucleotides for use in genetic research, pharmaceutical therapies, medical research and treatment of various conditions and disorders;oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; oligonucleotide compounds for use in the targeted delivery of rnai therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies;research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of liver-based disorders; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, chronic liver diseases, cardiovascular diseases, and viral infections;.

Its status is currently believed to be active. Its class is unavailable. “GALXC” is believed to be currently owned by “Dicerna Pharmaceuticals, Inc.”